{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:53:46Z","timestamp":1794412426364,"version":"4.9.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ekir.2025.103745","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:43:04Z","timestamp":1766594584000},"page":"103745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fulacimstat Reduces Angiotensin II in Kidney Allografts in a Cross-Sectional Exploratory Study"],"prefix":"10.1016","volume":"11","author":[{"given":"Johannes J.","family":"Kovarik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Tinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Schmetterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Kaltenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.103745_bib1","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ekir.2025.103745_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.tp.0000437676.32082.fc","article-title":"Questioning the myth: benefits of renin-angiotensin system blockade in kidney transplant recipients","volume":"97","author":"Wong","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2025.103745_bib3","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1681\/ASN.2006050543","article-title":"No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report","volume":"17","author":"Opelz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103745_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/TP.0000000000001140","article-title":"Angiotensin-converting enzyme inhibitors-beneficial effects seen in many patient groups may not extend to kidney transplant recipients","volume":"100","author":"Cross","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2025.103745_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/01.TP.0000437672.78716.28","article-title":"Cardiovascular death in kidney recipients treated with renin- angiotensin system blockers","volume":"97","author":"Opelz","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2025.103745_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","article-title":"Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial","volume":"4","author":"Knoll","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.103745_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/1947-2714.187141","article-title":"The effect of renin-angiotensin system inhibitors on kidney allograft survival: a systematic review and meta-analysis","volume":"8","author":"Cheungpasitporn","year":"2016","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.ekir.2025.103745_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.103745_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1681\/ASN.2010040384","article-title":"Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis","volume":"22","author":"Ruster","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103745_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028501","article-title":"Chymase-dependent generation of angiotensin II from angiotensin-(1\u201312) in human atrial tissue","volume":"6","author":"Ahmad","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.103745_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/1440-1681.12549","article-title":"Improvement of cardiovascular remodelling by chymase inhibitor","volume":"43","author":"Takai","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ekir.2025.103745_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCRESAHA.117.310978","article-title":"Multifunctional role of chymase in acute and chronic tissue injury and remodeling","volume":"122","author":"Dell\u2019Italia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2025.103745_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1525-139X.2011.00921.x","article-title":"Increased plasma chymase concentration and mast cell chymase expression in venous neointimal lesions of patients with CKD and ESRD","volume":"24","author":"Wasse","year":"2011","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2025.103745_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIRCRESAHA.119.316151","article-title":"Critical role of neprilysin in kidney angiotensin metabolism","volume":"127","author":"Kaltenecker","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2025.103745_bib15","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1097\/01.ASN.0000071512.93927.4E","article-title":"Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease","volume":"14","author":"Huang","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103745_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.105.575589","article-title":"Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications","volume":"113","author":"Koka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.103745_bib17","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.2001.0590041374.x","article-title":"Mast cell chymase expression and mast cell phenotypes in human rejected kidneys","volume":"59","author":"Yamada","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103745_bib18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI39345","article-title":"Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents","volume":"120","author":"Wei","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.103745_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.healun.2016.08.022","article-title":"Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients","volume":"36","author":"Kovarik","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ekir.2025.103745_bib20","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1038\/s41598-019-46114-x","article-title":"Intrarenal renin-angiotensin-system dysregulation after kidney transplantation","volume":"9","author":"Kovarik","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.103745_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.RES.74.6.1141","article-title":"Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells","volume":"74","author":"Griendling","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2025.103745_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mce.2008.11.003","article-title":"NADPH oxidases and angiotensin II receptor signaling","volume":"302","author":"Garrido","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ekir.2025.103745_bib23","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.172.4.2522","article-title":"Involvement of reactive oxygen species in toll-like receptor 4-dependent activation of NF-kappa B","volume":"172","author":"Asehnoune","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2025.103745_bib24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1096\/fj.00-0273com","article-title":"Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase","volume":"15","author":"Lindstedt","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.ekir.2025.103745_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/jcm9010253","article-title":"Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair","volume":"17","author":"Nieuwenhuijs-Moeke","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2025.103745_bib26","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury","volume":"121","author":"Bonventre","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.103745_bib27","article-title":"A novel chymase inhibitor BAY 1142524 reduces fibrosis and improves cardiac function after myocardial infarction in hamster","volume":"136","author":"Tinel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.103745_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cpdd.579","article-title":"Pharmacokinetics, safety, and tolerability of the novel chymase inhibitor BAY 1142524 in healthy male volunteers","volume":"8","author":"Kanefendt","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ekir.2025.103745_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/srep33678","article-title":"Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney","volume":"6","author":"Domenig","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.103745_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103745_bib31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/CIRCRESAHA.120.317624","article-title":"New insights into the renin-angiotensin system in chronic kidney disease","volume":"127","author":"Laffer","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2025.103745_bib32","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfaa299","article-title":"Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial","volume":"36","author":"Rossing","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103745_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/157340212800505007","article-title":"Impact of mast cell chymase on renal disease progression","volume":"8","author":"Wasse","year":"2012","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.ekir.2025.103745_bib34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.103745_bib35","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.jacc.2016.10.017","article-title":"Renin-angiotensin system fingerprints of heart failure with reduced ejection fraction","volume":"68","author":"Pavo","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.103745_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ahj.2020.01.012","article-title":"Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after myocardial infarction (CHIARA MIA) 2 trial","volume":"224","author":"Duengen","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ekir.2025.103745_bib37","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1021\/bi00383a030","article-title":"Slow-binding inhibition of chymotrypsin and cathepsin G by the peptide aldehyde chymostatin","volume":"26","author":"Stein","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.ekir.2025.103745_bib38","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1021\/acs.jmedchem.4c01819","article-title":"Discovery and preclinical characterization of Fulacimstat (BAY 1142524), a potent and selective chymase inhibitor as a new profibrinolytic approach for safe thrombus resolution","volume":"68","author":"F\u00fcrstner","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.ekir.2025.103745_bib39","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ekir.2025.103745_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacbts.2019.11.006","article-title":"Reduced left atrial emptying fraction and chymase activation in pathophysiology of primary mitral regurgitation","volume":"5","author":"Butts","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ekir.2025.103745_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.it.2020.06.006","article-title":"Cardiac mast cells: underappreciated immune cells in cardiovascular homeostasis and disease","volume":"41","author":"Varricchi","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ekir.2025.103745_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/ndt\/gfz058","article-title":"Chronic kidney disease, heart failure and neprilysin inhibition","volume":"35","author":"Haynes","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103745_bib43","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/ajh\/hpv054","article-title":"Plasma and kidney angiotensin peptides: importance of the aminopeptidase A\/angiotensin III axis","volume":"28","author":"Wysocki","year":"2015","journal-title":"Am J Hypertens"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:35:10Z","timestamp":1773984910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925007636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2468024925007636"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103745","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fulacimstat Reduces Angiotensin II in Kidney Allografts in a Cross-Sectional Exploratory Study","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103745"}}